- Glaukos submitted an investigational new drug application to the FDA for an intraocular travoprost implant that uses their iDose sustained delivery system (a hollow titanium container filled with drug, with a membrane cap that regulates drug release, that’s placed via a clear corneal incision into the anterior chamber. Glaukos will commence a 12-week Phase II trial comparing two travoprost elution rates with topical 0.5% timolol maleate.
- Interim results from Allergan’s Phase I/II trial of single-dose, sustained-release intracameral bimatoprost-eluting implant have yielded positive safety and efficacy results. Four months into the 24-month trial, 92 percent of patients with open angle glaucoma exhibited a decrease in IOP, and at 6 months, 71 percent of patients still had no need for either topical rescue or a second injection of bimatoprost. Not one of the 75 patients enrolled into the trial experienced serious adverse events.
- ALPHAEON, a self-described “social commerce company,” has announced an agreement to acquire LENSAR, makers during refractive and cataract surgery. ALPHAEON has also entered into an agreement with PhysIOL, an intraocular lens manufacturer with a broad portfolio of products including an aspheric trifocal diffractive lens known as the FineVision. Together, the companies plan to develop and commercialize a specialized, ALPHAEON-branded trifocal lens. ALPHAEON’s chief executive officer, Robert E. Grant, has made it clear that dysfunctional lens syndrome is a new target for his company. Alphaeon have had a busy month – in mid-November , they announced the purchase of Integrity Digital Solutions LLC, an ophthalmology/optometry electronic medical records company.
False
Advertisement
Related Content
Newsletters
Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.
False
Advertisement